Apogee Therapeutics (APGE) is modestly higher in Tuesday trading as biotech investors continue to build positions into the company’s next near-term clinical catalyst: 16-week induction data from APEX Phase 2 Part B, expected in Q2 2026. The move comes after Apogee’s March 23, 2026 update showing positive 52-week maintenance data from APEX Phase 2 Part A for zumilokibart (APG777) in moderate-to-severe atopic dermatitis, including durable maintenance metrics across 3- and 6-month dosing regimens and a safety profile described as generally consistent with agents in the class.

The March 23 release helped strengthen the core bull case that zumilokibart could compete not just on efficacy but on dosing convenience, with Apogee highlighting potential for quarterly or even twice-yearly maintenance dosing in atopic dermatitis. That positioning has kept the name in focus ahead of the Part B dose-optimization readout, which is designed to identify an optimized regimen and support a planned Phase 3 start in the second half of 2026.

APGE’s advance is also supported by recent momentum: the stock set an all-time high near $85.95 on April 9, 2026, as traders revisited the company’s pipeline narrative and the capital raised in its March 2026 underwritten offering. A stronger balance sheet and an active 2026 catalyst calendar can amplify day-to-day moves as positioning shifts around upcoming data.